Latest Novartis Stories
DUBLIN, January 27, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/n68kp7/pediatric_drugs) has announced the addition of the "Pediatric
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide BASEL, Switzerland, Jan.
- Array to receive global rights from Novartis to innovative BRAF inhibitor - BOULDER, Colo., Jan. 23, 2015 /PRNewswire/ -- Array BioPharma Inc.
Ohio Farmers Join Other Corn Growers Who Have Filed Syngenta GMO Corn Seed Lawsuits Over The Company’s Exporting of its Genetically Modified Corn Seed Without First Receiving China’s Approval
NEW HAVEN, Conn., Jan.
- Novartis returns Alisporivir (DEB025) to Debiopharm Group(TM) including all rights for HCV and other indications - LAUSANNE, Switzerland, January 12, 2015 /PRNewswire/ --
- The company describes refinements to its innovation-based strategy, including greater focus on core therapeutic areas and key geographies. INDIANAPOLIS, Jan.
MUMBAI and BALTIMORE, January 6, 2015 /PRNewswire/ -- Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc.